Treatment of latent tuberculosis in a child with mucopolysaccharidosis type I receiving enzyme replacement therapy: A case report.
enzyme replacement therapy (ERT)
laronidase
latent tuberculosis treatment
mucopolysaccharidosis type I
multi drug resistant tuberculosis (MDR-TB)
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
06
2022
accepted:
30
07
2022
entrez:
2
9
2022
pubmed:
3
9
2022
medline:
3
9
2022
Statut:
epublish
Résumé
Mucopolysaccharidosis type I S (MPS IS) is a rare autosomal recessive lysosomal storage disorder caused by mutations in the
Identifiants
pubmed: 36052356
doi: 10.3389/fped.2022.973193
pmc: PMC9424730
doi:
Types de publication
Case Reports
Langues
eng
Pagination
973193Informations de copyright
Copyright © 2022 Vasilevska, Kreile, Grinfelde and Skangale.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Hum Genet. 1990 Nov;47(5):802-7
pubmed: 2220820
Cell. 2016 Mar 24;165(1):139-152
pubmed: 27015311
Lancet Respir Med. 2019 Aug;7(8):653-654
pubmed: 31221567
MMWR Recomm Rep. 2020 Feb 14;69(1):1-11
pubmed: 32053584
Diagnostics (Basel). 2020 Mar 16;10(3):
pubmed: 32188113
Pediatrics. 2021 Dec 1;148(6):
pubmed: 34851422